TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00560222

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: bovine lactoferrin
Description: 1gm of lactoferrin will be given each day
Study: NCT01484418

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Psychotherapy
Description: graded activity, relaxation techniques and cognitive interventions
Study: NCT00862238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Messaging
Description: 4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, \& C
Study: NCT00560222

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo [maltodextrin]
Description: placebo that appears identical to lactoferrin will be given daily
Study: NCT02373241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Standard dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Experimental dosing
Study: NCT03798184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-carious cervical lesion restoration
Description: Restoration of non-carious cervical lesions with Prime\&Bond Active in self-etch or selective-etch mode with or without bioglass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-carious cervical lesion restoration
Description: Restoration of non-carious cervical lesions with Prime\&Bond Active in self-etch or selective-etch mode with or without bioglass

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-carious cervical lesion restoration
Description: Restoration of non-carious cervical lesions with Prime\&Bond Active in self-etch or selective-etch mode with or without bioglass
Study: NCT03926455

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Typhim Vi
Description: A single dose of commercial typhoid fever vaccine Typhim Vi is administered on Day 0, followed by placebo control on Day 28
Study: NCT03279653

Intervention type: PROCEDURE
Intervention: SleeveGastrectomy
Description: Preoperative enzyme test before and after sleeve gastrectomy. Sleeve Gastrectomy will be performed. Preoperative (in one month) and Postoperative (after 3 months) pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
Study: NCT03798184

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-carious cervical lesion restoration
Description: Restoration of non-carious cervical lesions with Prime\&Bond Active in self-etch or selective-etch mode with or without bioglass
Study: NCT03809221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin acetate
Description: Achieve pituitary down regulation with triptorelin acetate and start controlled ovarian stimulation after complete pituitary down regulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin acetate
Description: Achieve pituitary down regulation with triptorelin acetate and start controlled ovarian stimulation after complete pituitary down regulation
Study: NCT02094053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2020-Donepezil hydrochloride
Description: 3 mg of E2020 (oral) once daily, for 24 weeks
Study: NCT01317992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast
Description: Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.
Study: NCT02094053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2020-Donepezil hydrochloride
Description: 5 mg of E2020 (oral) once daily, for 24 weeks
Study: NCT01317992

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 capsules, orally, twice daily for 8 weeks.
Study: NCT01098747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel Ibuprofen
Description: Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ibuprofen
Description: Single-dose of standard ibuprofen (400mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ibuprofen
Description: Single-dose of standard ibuprofen (400mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose of placebo
Study: NCT02094053

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (oral) once daily, for 24 weeks
Study: NCT04343209

Intervention type: DIAGNOSTIC_TEST
Intervention: Myocardial Perfusion Imaging Study
Description: Evaluation of myocardial perfusion via PET imaging agent

Intervention type: DRUG
Intervention: AMMONIA N-13 37.5 mCi in 1 mL INTRAVENOUS INJECTION [Ammonia N 13]
Description: Cardiac PET imaging agent
Study: NCT04268472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP30101
Description: Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prezista®
Description: Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP30101
Description: Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prezista®
Description: Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
Study: NCT01093001

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Echo
Description: Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Echo
Description: Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Echo
Description: Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Echo
Description: Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
Study: NCT01896349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Study: NCT00862238

Intervention type: OTHER
Group type: OTHER
Intervention: Health Promotion
Description: 4 session education which offers basic information about the prevention of hepatitis A, B, \& C
Study: NCT04660890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: ALXN2050 will be administered orally twice daily as powder-in-capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALXN2050-matching Placebo
Description: ALXN2050-matching placebo will be administered orally twice daily as placebo powder-in-capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALXN2050-matching Placebo
Description: ALXN2050-matching placebo will be administered orally twice daily as placebo powder-in-capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin will be administered as a single oral dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin will be administered as a single oral dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin-matching Placebo
Description: Moxifloxacin-matching placebo will be administered as a single oral dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin-matching Placebo
Description: Moxifloxacin-matching placebo will be administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-matching Placebo
Description: Moxifloxacin-matching placebo will be administered as a single oral dose.
Study: NCT03842735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and rehabilitation counselling
Description: The intervention consists in a standardized physical exercise (PE) and rehabilitation counselling indications (RCI). PE is done 5 days/week (2 days in autonomy by the patient with parents support and 3 days supervised). Each session lasts 30 minutes and this is supervised by one therapist for all patients. Patients are enrolled in an EP composed by three different types of exercises, each carried out for 10 minutes per session: muscle strength exercises for upper and lower extremities preceded by warming up, aerobic exercises and stretching. The kind of exercise is differentiated by age range (children, 5-12 years and adolescents, 13-18 years).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehabilitation counselling
Description: RCI, which have to be followed daily, consist in some practical advice was given on how to adopt an active lifestyle during the recovery (e.g., getting up to go to the bathroom, getting up to move to the window to talk with visitors, sit on chair to have school lessons).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: rehabilitation counselling
Description: RCI, which have to be followed daily, consist in some practical advice was given on how to adopt an active lifestyle during the recovery (e.g., getting up to go to the bathroom, getting up to move to the window to talk with visitors, sit on chair to have school lessons).
Study: NCT05361460

Intervention type: OTHER
Intervention: Cognitive decline
Description: This is an observation study with the aim of explore patients' experiences of their early and late postoperative cognition after major orthopaedic surgery in relation to postoperative cognitive function assessed with validated neuropsychological tests, inflammatory signalling molecules and quality of postoperative recovery as well as to describe the relative's view of early postoperative cognition.
Study: NCT03170375

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Performance of WHEELS-I in promoting DASH/SRD adoption
Description: Participants will receive the WHEELS-I electronically-delivered tailored messaging intervention in addition to motivational interviewing-based counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performance of WHEELS-I in promoting DASH/SRD adoption
Description: Participants will receive the WHEELS-I electronically-delivered tailored messaging intervention in addition to motivational interviewing-based counseling.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Effects of a 2-week DASH/SRD intervention vs. control diet on HFpEF functional cardiovascular risk factors
Description: Participants will be randomized to the sequence DASH/SRD-control diet or control diet-DASH/SRD, and consume the diets for 14 days each.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effects of a 2-week DASH/SRD intervention vs. control diet on HFpEF functional cardiovascular risk factors
Description: Participants will be randomized to the sequence DASH/SRD-control diet or control diet-DASH/SRD, and consume the diets for 14 days each.
Study: NCT02398812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication assessment and treatment plan based on it
Description: Intervention~* Phase I: A medication assessment conducted by an interprofessional team including nurse, pharmacist and physician. The assessment is based on current medication list and basic information cathered by nurse.~* Phase II: This phase is needed if the assessment cannot be conducted safely without physical examination conducted by physician. The comprehensive interprofessional assessment takes place after the clinical examination conducted by home care physician.
Study: NCT02239926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: On January 31, 2006, ranolazine was approved for use in the United States by the Food and Drug Administration (FDA) for the treatment of chronic angina pectoris.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02704208

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Thrive With Me Control
Description: Those assigned to the TWM control group will receive a weekly email with static HIV informational content. Information will be focused more on quality of life and general wellbeing issues and will not be specific to medication adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive With Me Intervention
Description: Those assigned to the TWM intervention will have 150 days to access tailored content on a mobile-enhanced website. They will also have social support through a network of other HIV-positive men. Finally they will track their daily ART medication adherence and mood through SMS and website use.
Study: NCT04212663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The tendon release of musculi tibialis posterior
Description: To release the tendon of musculi tibialis posterior.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Anterior tibial tendon transfer(TATT)
Description: To transfer the the tendon of anterior tibial from the navicular to the third cuneiform.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior tibial tendon transfer(TATT)
Description: To transfer the the tendon of anterior tibial from the navicular to the third cuneiform.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Achilles tendon lengthing
Description: To lengthen the achilles tendon by using two incisions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Achilles tendon lengthing
Description: To lengthen the achilles tendon by using two incisions.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fascial release
Description: To cut off the metatarsal fascia in the middle part.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascial release
Description: To cut off the metatarsal fascia in the middle part.
Study: NCT01652781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: 5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
Study: NCT03590886

Intervention type: OTHER
Intervention: total response Group
Description: biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
Study: NCT01041430

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: day surgery group
Description: inguinal hernia repair, discharge from the hospital on the day of surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inpatient group
Description: inguinal hernia repair, patient admitted overnight to hospital
Study: NCT01528579

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck Specific Exercises
Description: 2 times a week for 3 months followed by encourages to continue on their own

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral approach combined with neck specific exercises
Description: Behavioral physiotherapeutic approach combined with neck specific exercises 2 times a week for 3 months. Exercises will be chosen from a well defined and structured frame of exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prescribed Physical activity
Description: Physical activity without neck specific exercises for 3 months
Study: NCT01561833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be allowed depending on the type and severity of toxicity encountered provided that criteria for patient withdrawal from study treatment have not been met.
Study: NCT05749471

Intervention type: DIAGNOSTIC_TEST
Intervention: ASEX (Arizona Sexual Experience) administration
Description: ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30. Generally, a subject with a total ASEX score of \> 19, any one item with a score of \> 5, or any three items with a score of \> 4 would have sexual dysfunction.
Study: NCT03917030

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement with osteoplasty
Description: Treatment of furcation grade II defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to \>90 degrees relative to the apico-coronal axis of the toot.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement with osteoplasty
Description: Treatment of furcation grade II defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to \>90 degrees relative to the apico-coronal axis of the toot.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement without osteoplasty
Description: Treatment of furcation grade II defect with open flap debridement only.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement without osteoplasty
Description: Treatment of furcation grade II defect with open flap debridement only.
Study: NCT02121509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 1 x Linagliptin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 1 x Linagliptin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 1 x Linagliptin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 1 x Linagliptin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin ER FDC
Description: 2 x Linagliptin/Metformin ER FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin ER FDC
Description: 2 x Linagliptin/Metformin ER FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin ER FDC
Description: 2 x Linagliptin/Metformin ER FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin ER FDC
Description: 2 x Linagliptin/Metformin ER FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: 3 x Metformin ER tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: 3 x Metformin ER tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: 3 x Metformin ER tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: 3 x Metformin ER tablets
Study: NCT03493958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using the Internet (SHUTi)
Description: The SHUTi program is an automated, interactive, internet-based intervention based on well-established face-to-face cognitive behavioral therapy for insomnia (CBT-I) components including sleep restriction, stimulus control, sleep hygiene, cognition
Study: NCT00586794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 3x per day 20 mg TID
Study: NCT01896349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranylcypromine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranylcypromine
Study: NCT00586794

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3x per day, 20 mg TID
Study: NCT00815386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous transvenous mitral annuloplasty
Description: Catheterization procedure with anesthesia requiring subclavicular puncture, catheterization of the right atrium and coronary sinus vein, placement and optimization of the PTMA device with access hub remaining subcutaneous at the clavicle.
Study: NCT02367963

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Training period
Description: Six workshops in which education on health habits and encouragement to reduce risk factors was promoted. Workshops addressed rigorous, accurate and effective technical information but were tailored to general public to ensure that subjects became aware of the importance of change in their overall health. Workshops led by experts dealt with the following relevant subjects: Motivation to Change; Physical Activity, Healthy Diet, Smoking Cessation; Stress Management and Self-control of Blood Pressure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training period
Description: Six workshops in which education on health habits and encouragement to reduce risk factors was promoted. Workshops addressed rigorous, accurate and effective technical information but were tailored to general public to ensure that subjects became aware of the importance of change in their overall health. Workshops led by experts dealt with the following relevant subjects: Motivation to Change; Physical Activity, Healthy Diet, Smoking Cessation; Stress Management and Self-control of Blood Pressure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-group
Description: The ultimate goal is to reinforce the self-accountability in the subjects and nurture their self-care. It is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.